Zevor-cel (CT053)3
Zevor-cel (CT053)
Zevor-cel (CT053)
Conventional
Zevorcabtagene autoleucel (Zevor-cel, R&D code: CT053) is a fully human, autologous BCMA CAR T-cell product for the treatment of R/R MM. Zevorcabtagene autoleucel was approved by the NMPA on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (at least one proteasome inhibitor and immunomodulator).
Phase 1b/2 Clinical Trial (LUMMICAR STUDY 2)
for relapsed and/or refractory multiple myeloma (R/R MM)
for multiple myeloma (MM)
Conventional
Satri-cel (CT041)
Satri-cel (CT041)
Satri-cel (CT041)
Conventional
CT041 is an autologous CAR T product candidate that targets Claudin18.2 (“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.
for advanced gastric /gastroesophageal junction adenocarcinoma (GC/GEJ) with Claudin18.2-positive tumor
for gastric /gastroesophageal junction cancer (GC/GEJ)
Breakthrough Therapy designation, NMPA
for advanced gastric/gastroesophageal junction cancer (G/GEJ) in patients who have failed at least two prior lines of therapy.
Conventional
CT071
CT071
CT071
CARcelerate®
CT071 is a CAR T-cell therapy candidate developed utilizing our proprietary CARcelerate® platform, targeting GPRC5D. CARcelerate® platform can shorten the manufacturing time for the CAR T cells to about 30 hours.
CARcelerate®
CT011
CT011
CT011
Conventional
CT011 is an autologous CAR T product candidate that targets glypican-3 (GPC3), which is highly expressed in HCC and is suggested to be a prognostic marker for the disease.
Conventional
CT0590
CT0590
CT0590
THANK-uCAR®
CT0590 is an allogeneic CAR T-cell therapy developed utilizing our proprietary THANK-uCAR® platform, targeting BCMA and NKG2A (a membrane protein expressed in NK and T cells), and a triple knockout for TRAC/B2M/NKG2A which allows it to avoid graft-versus-host disease (GvHD) and host-versus-graft reaction (HvGR), making it fratricide-resistant while enhancing its immune function.
THANK-uCAR®
CT0596
CT0596
CT0596
THANK-u Plus™
CT0596 is an allogeneic BCMA-targeted CAR-T therapy developed using CARsgen’s proprietary THANK-u Plus™ platform. CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals and CAR-T expansion across all predefined dose levels.
THANK-u Plus™
THANK-uCAR®
THANK-uCAR®
THANK-uCAR®
THANK-uCAR®
R/R MM: relapsed/refractory multiple myeloma; GC: gastric cancer; GEJ: gastroesophageal junction cancer; PC: pancreatic cancer; HCC: hepatocellular carcinoma; R/R pPCL: relapsed/refractory primary plasma cell leukemia; NDMM: newly diagnosed multiple myeloma; SLE: systemic lupus erythematosus; SSc: systemic sclerosis; AML: acute myeloid leukemia
1 All product candidates are self-developed with global rights
2 Phase II trials of some indications are pivotal studies
3 Core Product Candidate. Commercial rights in mainland China have been granted to Huadong Medicine (SZ: 000963). Rights in the South Korean market have been licensed out to HK Inno.N (KOSDAQ: 195940)